Expertise
Lymphoma, Leukemia ( CLL, SLL), Multiple Myeloma and Related Blood Cancer, Hairy Cell.
The Rosenblatt laboratory is engaged in the development of novel targeted therapeutic approaches including antibody fusion proteins directed at known cancer antigens such as EGFR, HER2 and CD20 that are designed to deliver a fused biological payload, which can inhibit angiogenesis, vasculogenic mimicry and/or evoke an immune response against cancer cells. In addition the laboratory has been investigating the role of B regulatory cells in modulating antitumor immune response, and the potential for modulating B regulatory activity.
The Rosenblatt Lab focuses on the following:
1. Study the role of B regulatory cells in anti-tumor immunity.
2. Developing therapeutic anti-tumor antibody fusion proteins to inhibit both angiogenesis and vasculogenic mimicry.